ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SGYP Synergy Pharmaceuticals, Inc.

0.03
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Synergy Pharmaceuticals, Inc. NASDAQ:SGYP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.03 0.0488 0.049 0 01:00:00

Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences

06/09/2017 1:30pm

Business Wire


Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Synergy Pharmaceuticals, Inc. Charts.

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present corporate updates at three upcoming investor conferences in New York City during September:

Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 9:35 a.m. Eastern Time.

Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 10:20 a.m. Eastern Time.

Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 10:30 a.m. Eastern Time.

A live webcast of the presentations will be accessible through the Investor Relations section of the company’s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’s website for 90 days following each conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE™ (plecanatide) and a second lead product candidate, dolcanatide. For more information, please visit www.synergypharma.com.

Synergy Pharmaceuticals Inc.Gem Hopkins, 212-584-7610VP, Investor Relations and Corporate Communicationsghopkins@synergypharma.com

1 Year Synergy Pharmaceuticals, Inc. Chart

1 Year Synergy Pharmaceuticals, Inc. Chart

1 Month Synergy Pharmaceuticals, Inc. Chart

1 Month Synergy Pharmaceuticals, Inc. Chart

Your Recent History

Delayed Upgrade Clock